{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:47:10Z","timestamp":1792788430895,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pelotonia Idea Grant"},{"name":"OSU Division of Hematology-Sponsored Research Program grant"},{"name":"OSU Department of Internal Medicine Junior Investigator Award"},{"name":"OSU Drug Development Institute Pilot grant"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mantle cell lymphoma (MCL) is a rare B-cell non-Hodgkin lymphoma subtype which remains incurable despite multimodal approach including chemoimmunotherapy followed by stem cell transplant, targeted approaches such as the BTK inhibitor ibrutinib, and CD19 chimeric antigen receptor (CAR) T cells. CD74 is a nonpolymorphic type II integral membrane glycoprotein identified as an MHC class II chaperone and a receptor for macrophage migration inhibitory factor. Our group previously reported on CD74's abundant expression in MCL and its ability to increase via pharmacological inhibition of autophagosomal degradation. Milatuzumab, a fully humanized anti-CD74 monoclonal antibody, demonstrated significant activity in preclinical lymphoma models but failed to provide meaningful benefits in clinical trials mainly due to its short half-life. We hypothesized that targeting CD74 using a CAR-T cell would provide potent and durable anti-MCL activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We engineered a second generation anti-CD74 CAR with 4-1BB and CD3\u03b6 signaling domains (74bbz). Through in silico and rational mutagenesis on the scFV domain, the 74bbz CAR was functionally optimized for superior antigen binding affinity, proliferative signaling, and cytotoxic activity against MCL cells in vitro and in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Functionally optimized 74bbz CAR-T cells (clone 42105) induced significant killing of MCL cell lines, and primary MCL patient samples including one relapse after commercial CD19 CAR-T cell therapy with direct correlation between antigen density and cytotoxicity. It significantly prolonged the survival of an animal model established in NOD-SCID\u03b3c\n                      <jats:sup>\u2212\/\u2212<\/jats:sup>\n                      (NSG) mice engrafted with a human MCL cell line Mino subcutaneously compared to controls. Finally, while CD74 is also expressed on normal immune cell subsets, treatment with 74bbz CAR-T cells resulted in minimal cytotoxicity against these cells both in vitro and in vivo.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Targeting CD74 with 74bbz CAR-T cells represents a new cell therapy to provide a potent and durable and anti-MCL activity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40164-023-00437-8","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T08:02:57Z","timestamp":1695369777000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models"],"prefix":"10.1186","volume":"12","author":[{"given":"Wing Keung","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinnari","family":"Sorathia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy","family":"Pray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaled","family":"Abusaleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehua","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archisha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Hout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamama","family":"Nishat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Hanel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelby L.","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneeq","family":"Yasin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Denlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natarajan","family":"Muthusamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumithira","family":"Vasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Baiocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lapo","family":"Alinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,22]]},"reference":[{"issue":"26","key":"437_CR1","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMra2202672","volume":"386","author":"JO Armitage","year":"2022","unstructured":"Armitage JO, Longo DL. Mantle-cell lymphoma. N Engl J Med. 2022;386(26):2495\u2013506.","journal-title":"N Engl J Med"},{"issue":"5","key":"437_CR2","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.hoc.2020.05.002","volume":"34","author":"A Navarro","year":"2020","unstructured":"Navarro A, Be\u00e0 S, Jares P, Campo E. Molecular pathogenesis of mantle cell lymphoma. Hematol Oncol Clin North Am. 2020;34(5):795\u2013807.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"6","key":"437_CR3","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ajh.25487","volume":"94","author":"P Jain","year":"2019","unstructured":"Jain P, Wang M. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. Am J Hematol. 2019;94(6):710\u201325.","journal-title":"Am J Hematol"},{"issue":"13","key":"437_CR4","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1182\/bloodadvances.2019001350","volume":"4","author":"HA Hill","year":"2020","unstructured":"Hill HA, Qi X, Jain P, Nomie K, Wang Y, Zhou S, et al. Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis. Blood Adv. 2020;4(13):2927\u201338.","journal-title":"Blood Adv"},{"issue":"6","key":"437_CR5","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","volume":"26","author":"CY Cheah","year":"2015","unstructured":"Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Hagemeister FB, et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015;26(6):1175\u20139.","journal-title":"Ann Oncol"},{"issue":"1","key":"437_CR6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1182\/blood-2014-05-521898","volume":"125","author":"E Campo","year":"2015","unstructured":"Campo E, Rule S. Mantle cell lymphoma: evolving management strategies. Blood. 2015;125(1):48\u201355.","journal-title":"Blood"},{"issue":"3","key":"437_CR7","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1200\/JCO.19.01294","volume":"38","author":"HC Kluin-Nelemans","year":"2020","unstructured":"Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Geisler CH, Trneny M, et al. Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized european MCL elderly trial. J Clin Oncol. 2020;38(3):248\u201356.","journal-title":"J Clin Oncol"},{"issue":"6","key":"437_CR8","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507\u201316.","journal-title":"N Engl J Med"},{"issue":"13","key":"437_CR9","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","volume":"378","author":"CS Tam","year":"2018","unstructured":"Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018;378(13):1211\u201323.","journal-title":"N Engl J Med"},{"issue":"14","key":"437_CR10","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331\u201342.","journal-title":"N Engl J Med"},{"issue":"3","key":"437_CR11","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1200\/JCO.21.02370","volume":"41","author":"M Wang","year":"2023","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2023;41(3):555\u201367.","journal-title":"J Clin Oncol"},{"issue":"6 Pt A","key":"437_CR12","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.bbamcr.2016.03.026","volume":"1863","author":"B Schr\u00f6der","year":"2016","unstructured":"Schr\u00f6der B. The multifaceted roles of the invariant chain CD74\u2013More than just a chaperone. Biochim Biophys Acta. 2016;1863(6 Pt A):1269\u201381.","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"437_CR13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/ni.2225","volume":"13","author":"G Basha","year":"2012","unstructured":"Basha G, Omilusik K, Chavez-Steenbock A, Reinicke AT, Lack N, Choi KB, et al. A CD74-dependent MHC class I endolysosomal cross-presentation pathway. Nat Immunol. 2012;13(3):237\u201345.","journal-title":"Nat Immunol"},{"issue":"12","key":"437_CR14","doi-asserted-by":"publisher","first-page":"4807","DOI":"10.1182\/blood-2005-11-4334","volume":"107","author":"D Starlets","year":"2006","unstructured":"Starlets D, Gore Y, Binsky I, Haran M, Harpaz N, Shvidel L, et al. Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood. 2006;107(12):4807\u201316.","journal-title":"Blood"},{"issue":"12","key":"437_CR15","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1369\/jhc.4A6552.2005","volume":"53","author":"CA Barrera","year":"2005","unstructured":"Barrera CA, Beswick EJ, Sierra JC, Bland D, Espejo R, Mifflin R, et al. Polarized expression of CD74 by gastric epithelial cells. J Histochem Cytochem. 2005;53(12):1481\u20139.","journal-title":"J Histochem Cytochem"},{"issue":"2","key":"437_CR16","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1046\/j.1365-2567.1999.00868.x","volume":"98","author":"GL Ong","year":"1999","unstructured":"Ong GL, Goldenberg DM, Hansen HJ, Mattes MJ. Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines. Immunology. 1999;98(2):296\u2013302.","journal-title":"Immunology"},{"issue":"18 Pt 2","key":"437_CR17","doi-asserted-by":"publisher","first-page":"5556s","DOI":"10.1158\/1078-0432.CCR-07-1167","volume":"13","author":"R Stein","year":"2007","unstructured":"Stein R, Mattes MJ, Cardillo TM, Hansen HJ, Chang CH, Burton J, et al. CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res. 2007;13(18 Pt 2):5556s-s5563.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"437_CR18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/bjh.14726","volume":"182","author":"M Haran","year":"2018","unstructured":"Haran M, Mirkin V, Braester A, Harpaz N, Shevetz O, Shtreiter M, et al. A phase I\u2013II clinical trial of the anti-CD74 monoclonal antibody milatuzumab in frail patients with refractory chronic lymphocytic leukaemia: a patient based approach. Br J Haematol. 2018;182(1):125\u20138.","journal-title":"Br J Haematol"},{"issue":"26","key":"437_CR19","doi-asserted-by":"publisher","first-page":"6893","DOI":"10.1182\/blood-2011-06-363879","volume":"118","author":"L Alinari","year":"2011","unstructured":"Alinari L, Mahoney E, Patton J, Zhang X, Huynh L, Earl CT, et al. FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death. Blood. 2011;118(26):6893\u2013903.","journal-title":"Blood"},{"issue":"17","key":"437_CR20","doi-asserted-by":"publisher","first-page":"4530","DOI":"10.1182\/blood-2010-08-303354","volume":"117","author":"L Alinari","year":"2011","unstructured":"Alinari L, Yu B, Christian BA, Yan F, Shin J, Lapalombella R, et al. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood. 2011;117(17):4530\u201341.","journal-title":"Blood"},{"issue":"3","key":"437_CR21","doi-asserted-by":"publisher","first-page":"416","DOI":"10.4161\/auto.19050","volume":"8","author":"L Alinari","year":"2012","unstructured":"Alinari L, Baiocchi RA, Praetorius-Ibba M. FTY720-induced blockage of autophagy enhances anticancer efficacy of milatuzumab in mantle cell lymphoma: is FTY720 the next autophagy-blocking agent in lymphoma treatment? Autophagy. 2012;8(3):416\u20137.","journal-title":"Autophagy"},{"issue":"12","key":"437_CR22","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1182\/blood-2004-03-0890","volume":"104","author":"R Stein","year":"2004","unstructured":"Stein R, Qu Z, Cardillo TM, Chen S, Rosario A, Horak ID, et al. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood. 2004;104(12):3705\u201311.","journal-title":"Blood"},{"issue":"11","key":"437_CR23","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.3109\/10428194.2015.1028052","volume":"56","author":"P Martin","year":"2015","unstructured":"Martin P, Furman RR, Rutherford S, Ruan J, Ely S, Greenberg J, et al. Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas. Leuk Lymphoma. 2015;56(11):3065\u201370.","journal-title":"Leuk Lymphoma"},{"key":"437_CR24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/978-1-4939-8736-8_21","volume":"1851","author":"J Leem","year":"2019","unstructured":"Leem J, Deane CM. High-throughput antibody structure modeling and design using ABodyBuilder. Methods Mol Biol. 2019;1851:367\u201380.","journal-title":"Methods Mol Biol"},{"key":"437_CR25","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/978-1-0716-2609-2_14","volume":"2552","author":"F Ambrosetti","year":"2023","unstructured":"Ambrosetti F, Jandova Z, Bonvin AMJJ. Information-driven antibody-antigen modelling with HADDOCK. Methods Mol Biol. 2023;2552:267\u201382.","journal-title":"Methods Mol Biol"},{"issue":"6","key":"437_CR26","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nmeth0607-466","volume":"4","author":"S Yin","year":"2007","unstructured":"Yin S, Ding F, Dokholyan NV. Eris: an automated estimator of protein stability. Nat Methods. 2007;4(6):466\u20137.","journal-title":"Nat Methods"},{"issue":"5","key":"437_CR27","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","volume":"10","author":"RG Majzner","year":"2020","unstructured":"Majzner RG, Rietberg SP, Sotillo E, Dong R, Vachharajani VT, Labanieh L, et al. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov. 2020;10(5):702\u201323.","journal-title":"Cancer Discov"},{"issue":"1-2","key":"437_CR28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jim.2005.04.016","volume":"302","author":"CA Geuijen","year":"2005","unstructured":"Geuijen CA, Clijsters-van der Horst M, Cox F, Rood PM, Throsby M, Jongeneelen MA, et al. Affinity ranking of antibodies using flow cytometry: application in antibody phage display-based target discovery. J Immunol Methods. 2005;302(1\u20132):68\u201377.","journal-title":"J Immunol Methods"},{"issue":"6","key":"437_CR29","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.ymthe.2018.03.016","volume":"26","author":"EL Smith","year":"2018","unstructured":"Smith EL, Staehr M, Masakayan R, Tatake IJ, Purdon TJ, Wang X, et al. Development and evaluation of an optimal human single-chain variable fragment-derived BCMA-targeted CAR T cell vector. Mol Ther. 2018;26(6):1447\u201356.","journal-title":"Mol Ther"},{"issue":"5","key":"437_CR30","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1093\/bioinformatics\/btz779","volume":"36","author":"Y Myung","year":"2020","unstructured":"Myung Y, Rodrigues CHM, Ascher DB, Pires DEV. mCSM-AB2: guiding rational antibody design using graph-based signatures. Bioinformatics. 2020;36(5):1453\u20139.","journal-title":"Bioinformatics"},{"issue":"11","key":"437_CR31","doi-asserted-by":"publisher","first-page":"e1019","DOI":"10.1016\/j.clml.2022.07.017","volume":"22","author":"M Al-Mansour","year":"2022","unstructured":"Al-Mansour M. Treatment landscape of relapsed\/refractory mantle cell lymphoma: an updated review. Clin Lymphoma Myeloma Leuk. 2022;22(11):e1019\u201331.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"437_CR32","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","volume":"183","author":"KR Parker","year":"2020","unstructured":"Parker KR, Migliorini D, Perkey E, Yost KE, Bhaduri A, Bagga P, et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell. 2020;183(1):126-42.e17.","journal-title":"Cell"},{"issue":"4","key":"437_CR33","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/bjh.12565","volume":"163","author":"JL Kaufman","year":"2013","unstructured":"Kaufman JL, Niesvizky R, Stadtmauer EA, Chanan-Khan A, Siegel D, Horne H, et al. Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. Br J Haematol. 2013;163(4):478\u201386.","journal-title":"Br J Haematol"},{"issue":"23","key":"437_CR34","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.3748\/wjg.15.2855","volume":"15","author":"EJ Beswick","year":"2009","unstructured":"Beswick EJ, Reyes VE. CD74 in antigen presentation, inflammation, and cancers of the gastrointestinal tract. World J Gastroenterol. 2009;15(23):2855\u201361.","journal-title":"World J Gastroenterol"},{"issue":"39","key":"437_CR35","doi-asserted-by":"publisher","first-page":"eabo0514","DOI":"10.1126\/sciadv.abo0514","volume":"8","author":"P Rodriguez-Marquez","year":"2022","unstructured":"Rodriguez-Marquez P, Calleja-Cervantes ME, Serrano G, Oliver-Caldes A, Palacios-Berraquero ML, Martin-Mallo A, et al. CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome. Sci Adv. 2022;8(39):eabo0514.","journal-title":"Sci Adv"},{"issue":"13","key":"437_CR36","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1182\/blood-2017-02-764639","volume":"129","author":"L Alinari","year":"2017","unstructured":"Alinari L. Toward autophagy-targeted therapy in lymphoma. Blood. 2017;129(13):1740\u20132.","journal-title":"Blood"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-023-00437-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-023-00437-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-023-00437-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T16:50:15Z","timestamp":1700412615000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-023-00437-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,22]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["437"],"URL":"https:\/\/doi.org\/10.1186\/s40164-023-00437-8","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,22]]},"assertion":[{"value":"22 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The approval of the Institutional Review Board at The Ohio State University. All animal studies were approved by The Ohio State University Institutional Animal Care and Use Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests. A patent application has been filed for this CAR.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"79"}}